Targanta Finally Files New Antibiotic NDA
Cambridge, Mass-based Targanta Therapeutics announced Monday that it had finally submitted a new drug application to the U.S. Food and Drug Administration for its lead product, the antibiotic oritavancin. As mentioned in a previous post Targanta executives had decided to delay the submission of the oritavancin NDA.
Oritavancin is being touted as a viable option for treating antibiotic-resistant bacterial infections. It would compete in the marketplace against drugs including telavancin being developed by Theravance and cubicin, an antibiotic offered by Cubist Pharmaceuticals Inc to treat skin and blood infections.
Targanta has backed up its application with data from 19 clinical trials including two late-stage human clinical trials. More than 2,100 patients took part in the clinical testing of the drug.
I wish Targanta luck–we need new antibiotics!
Until next time…
Good Luck and Good Job Hunting
